If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
131
results.
Updated on
15/11/2026 [06:54:00]
Absstract of: US20260355308A1
A composition for an oral vaccine comprises nanoparticles containing an antigen and fibroin.
Absstract of: US20260356808A1
A novel ionizable lipid compound, lipid nanoparticles including the ionizable lipid compound, and uses thereof are disclosed. The novel ionizable lipid compound is represented by formula (I) or a salt thereof. Lipid nanoparticles including a novel ionizable lipid compound have excellent nucleic acid encapsulation efficiency and high cell delivery efficiency of nucleic acids. (Terminal area 1)j-connection1-headk-connection 2-(Terminal area 2)m Formula (I).
Absstract of: US20260355121A1
The current disclosure provides novel lipid nanoparticles comprising lung surfactants (Surf-LNPs) wherein said Surf-LNPs are useful for providing transfer of genetic material, i.e., nucleic acids, into cells and/or tissues of the lung or potentially other organs/tissues. Surf-LNPs comprise one or more biocompatible lipid components, one or more lung surfactants, and one or more nucleic acids encoding therapeutic agents, prophylactic agents or a combination thereof. The present disclosure further provides pharmaceutical compositions comprising said Surf-LNPs and their use in the treatment of lung disease. Said Surf-LNPs may also serve as vaccine compositions through the incorporation of nucleic acids therein which encode an immunogen or antigen of interest.
Absstract of: US20260355346A1
A hybrid biomimetic nanostructure platform for oral delivery of therapeutics to the central nervous system across dual biological barriers comprises a protective outer shell encapsulating a structured inner core that carries a therapeutic payload and a blood-brain barrier transcytosis moiety. The outer shell bears at least one microfold-cell targeting moiety on its exterior and resists gastrointestinal degradation. Following oral administration the microfold-cell targeting moiety directs transcytosis across the intestinal epithelium; the blood-brain barrier transcytosis moiety thereafter directs receptor-mediated transcytosis across brain capillary endothelium; and a stimulus-responsive element triggers payload release in central nervous system tissue. The platform enables oral administration of small molecule, peptide, protein, nucleic acid, and gene-editing payloads for treatment of neurological, neurodegenerative, neuroinflammatory, neuropsychiatric, neurodevelopmental, and neuro-oncologic conditions. A closed-loop system couples the composition to biomarker-driven dosing adjustment with clinician override.
Absstract of: US20260355234A1
Microbiome-ceria nanocompositions and methods for application of these nanocompositions to benefit human health. The nanocomposition formulations include cerium oxide nanoparticles combined with proteins and/or other bioactive agents isolated from commensal microbes such as Lactobacillus acidophilus (L. acidophilus).
Absstract of: US20260355125A1
Described herein are electrospun biodegradable flexible nanofiber membranes that retain therapeutic-loaded nanoparticles within fibers, providing localized drug delivery suitable for post-operative treatment of solid tumors. Poly(lactic-co-glycolic acid) fibers retain doxorubicin-loaded mesoporous silicon dioxide nanoparticles to form a drug-in-nanoparticle-in-fiber construct that provides a dual-barrier release architecture governed by nanoparticle pore diffusion and polymer-matrix diffusion and degradation to suppress burst release and provide sustained delivery. The flexible nanofiber membrane comprises coaxial or triaxial fibers that compartmentalize different payloads to provide staged time-release profiles, including a delayed-start release mediated by acidic pH lower than physiological pH, using a pH-responsive layer that increases porosity or permeability under acidic conditions. Representative methods include surfactant-templated synthesis of mesoporous silica nanoparticles, drug loading, dispersion into polymer solutions, electrospinning to form flexible nanofiber membranes, and in vitro characterization of morphology, chemical composition, release behavior, and cellular uptake in a non-small cell lung cancer cell model.
Absstract of: US20260355341A1
The invention relates to a lipid-based nanoparticle comprising an antigen-binding domain capable of specifically binding to a target expressed on activated immune cells surface and one or several mRNA molecule(s) encoding an activity-enhancing protein of said activated immune cells, and to uses thereof.
Absstract of: AU2026257536A1
The present disclosure relates to self-replicating RNA encoding an antigen from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and uses thereof. Specifically, the disclosure provides a self-replicating RNA or a monocistronic self- replicating RNA comprising a nucleotide sequence encoding an antigen operably linked to a subgenomic promoter, wherein the antigen is from SARS-CoV-2, and wherein the antigen is a spike (S) protein or a nucleocapsid (N) protein. ct c t
Absstract of: US20260355339A1
The present invention relates to solid microbeads having an anti-CD28 monoclonal antibody immobilized thereto for use in the local treatment of malignant melanoma, wherein the anti-CD28 monoclonal antibody binds to an epitope on CD28 outside the C″ D loop. The present invention further relates to methods for the local treatment of malignant melanoma comprising the administration of said microbeads.
Absstract of: US20260355352A1
A nitrogen-branched non-linear PEGylated lipid containing a tertiary amine, which is represented by the Formula (1); wherein, B1 and B2 are linking bonds or alkylene groups; L1, L2, Ld and Lx are linking bonds or divalent linking groups L; R1 and R2 are C1-50 aliphatic hydrocarbon groups or C1-50 residues of aliphatic hydrocarbon derivative, each containing 0-10 heteroatoms; Ncore is a multivalent group of valence y+1 and contains a trivalent nitrogen-atom branching core connected to Ld; y is 2, 3, 4, 5, 6, 7, 8, 9, or ≥10; XPEG are polyethylene glycol components. Compared with linear PEGylated lipids, the nitrogen-branched PEGylated lipid herein can realize better surface modification of LNP. The present invention also provides a lipid pharmaceutical composition and its formulation containing the PEGylated lipid, which can enhance the targeting ability of drugs and improve the transfection efficiency of nucleic acid drugs.
Absstract of: US20260355224A1
Disclosed herein are methods for managing disorders or conditions, or treating symptoms of disorders or conditions, comprising administering 5HT receptor agonists. The disorders may involve cognitive function and the methods of improving may comprise administering low doses of 5HT receptor agonists to subjects in need thereof. Improvement of the symptoms of a disorder involving cognitive function can be achieved where the disorders comprise mood, cognitive, anxiety, and depression disorders. Also disclosed herein are pharmaceutical compositions, formulations, and dosage forms of 5HT receptor agonists.
Absstract of: US20260356793A1
The present invention discloses a novel cationic lipid and a method for preparing the same, a lipid composition containing said cationic lipid and an LNP-drug composition and a formulation thereof containing the lipid composition, in particular, the LNP-pharmaceutical composition and the formulation thereof containing the cationic lipid, which is characterized by high delivery efficiency and high biocompatibility, thereby improving the therapeutic and preventive effects of the drug. The structure of the cationic lipid is shown in the general formula (1), and the definition of each symbol in the formula is described in the text.
Absstract of: US20260355111A1
The present disclosure relates to a protocol for the formulation and lyophilization of hydroxyl-terminated poly(ethylene glycol) (PEG) based block copolymer micelles without the use of excipients (cryo-protectants). The micelles are formulated using the equilibrium nanoprecipitation (ENP) method, which allows for control over the aggregation number of the micelles and thus the grafting density of the PEG micelle corona chains. By using the ENP method to produce micelles with high dimensionless PEG grafting densities (> about 7), the micelles are stabilized against aggregation during lyophilization due to the shielding of the micelle core domains by the dense PEG corona chains. By preventing aggregation during the lyophilization without using excipients, the original desired surface mechanical properties of the micelles are preserved after reconstitution. Therefore, the protocol described herein can be applied to effectively storing PEG-based block copolymer micelles without using excipients while still preserving their original surface mechanical properties.
Absstract of: US20260355124A1
The present disclosure relates to a method for preparing extracellular vesicles with reduced non-specific binding/endocytosis. By means of performing knockout and deglycosylation operations on extracellular vesicle-associated adhesion molecules, extracellular vesicles with reduced non-specific binding/endocytosis are obtained, and the circulation time thereof in the blood is pro-longed. Furthermore, an IL-12 combined antibody is loaded onto the extracellular vesicles with reduced non-specific binding/endocytosis to achieve enhanced efficacy of IL-12 in a “multimer” mode, which further achieves targeting by means of the antibody, reducing an initial concentration of IL-12 and improving safety while also achieving efficient inhibition of tumor growth at a certain level of safety.
Absstract of: US20260356882A1
Provided herein are methods for functionalizing nanoparticles with functional proteins, and methods of using the functionalized nanoparticles. Compositions for preparing the functionalized nanoparticles are also described herein.
Absstract of: US20260355117A1
The present disclosure provides a particulate delivery system comprising an extracted yeast cell wall comprising beta-glucan and a pro-payload molecule comprising a payload scaffolding molecule operably and reversibly linked to a payload molecule through a cleavable linker. The disclosure further provides methods of making and methods of using the particulate delivery system.
Absstract of: AU2025243613A1
The present invention relates to formulations, devices and methods for coating surfaces of microprojections on microprojection arrays with nucleic acids. The present invention also relates to formulations and methods for coating surfaces of microprojections with nucleic acids where the nucleic acids are associated with lipid nanoparticles (LNP), in particular where the nucleic acid is mRNA.
Absstract of: US20260355114A1
Hyaluronic acid polymers may be converted to derivatives thereof by reaction with divinyl sulfone to provide vinyl sulfone substituted polymers, where the polymers may additionally be further derivatized, including crosslinked, and the crosslinked and non-crosslinked derivatives may be used in biomedical and other applications.
Absstract of: AU2025433234A1
The present invention relates to an apparatus for softening a crystalline lens nucleus (100) in a cataract phacoemulsification treatment comprising an electric current pulse generator (11) to supply a pulse current to a handpiece (12), wherein the pulse current generates a pulsatile magnetic field, and to hydrodissect the lens nucleus with iron oxide nanoparticle solution to loosen the lens nucleus as well as to infiltrate the lens nucleus (14) with the iron oxide nanoparticles (13), characterised in that the needle tip (24) of the handpiece (12) conducts the generated pulsatile magnetic field to the lens nucleus which causes vibration of iron oxide nanoparticles which emanates a mechanical force to break interdigitating bonds between lens fibers, leading to a controlled softening and fragmenting of the lens nucleus, wherein the electric current pulse generator (11) is configured to produce pulse currents with adjustable voltage and frequency parameters, and the iron oxide nanoparticle solution (13) further comprises a superparamagnetic property functionalised with a biocompatible coating.
Absstract of: US20260355122A1
Disclosed is an ionizable lipid nanoparticle (LNP) composition having four lipid components: C12-200, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), cholesterol, and (1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-methoxy(polyethylene glycol)-2000 (ammonium salt)) (DMPE-PEG). The LNP composition is useful for delivering RNA to the placenta, thus also providing methods of treating placenta-related disorders.
Absstract of: US20260358332A1
This invention relates to magnetic clusters comprising nanocrystals of iron oxide. The magnetic clusters comprise an aromatic carboxylic acid and/or the magnetic clusters are monodisperse. The magnetic clusters may be useful in biological assays and other applications. The invention also relates to processes for preparing such magnetic clusters and methods of using the magnetic clusters, as well kits comprising the magnetic clusters.
Absstract of: US20260356906A1
The invention described herein provides an engineered insulin polypeptide comprising two cleavable peptides interposed between the insulin B-chain and the C-peptide, and between the C-peptide and the insulin A-chain to secrete active insulin from muscle cells. Also provides are polynucleotide encoding the engineered insulin for intramuscular delivery through Adeno Associated Virus (AAV) vectors, and the use thereof to treat diseases such as diabetes, hyperglycemia and other hyperglycemia-related diseases.
Absstract of: US20260355120A1
The present invention provides, in part, asymmetric “good” buffer-based cationic lipids of Formula (I′), and sub-formulas thereof:or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those caused by viral or bacterial infection.
Absstract of: US20260355119A1
The invention provides intranasal formulation for pulmonary delivery of nanoparticles, compositions, uses, and manufacturing methods thereof. In one aspect, an intranasal formulation for intranasal or intrapulmonary administration includes a viscosity agent, an epithelial adherence agent, and a foaming agent. The viscosity agent may include carboxymethylcellulose, the epithelial adherence agent may include poly-lysine, and the foaming agent may include gelatin hydrolysate.
Nº publicación: AU2025292967A1 12/11/2026
Applicant:
ARCUS BIOSCIENCES INC [US]
ARCUS BIOSCIENCES, INC.
Absstract of: AU2025292967A1
Pharmaceutical compositions of Compound (I) including solid dispersions of Compound (I) and nanocrystalline powder forms of Compound (I). Related unit dosage forms, and methods of making and using the same are also provided.
BOPI
Electronic site
